Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of blautia producta to preparation of products for strengthening treatment efficacy of blood lipid reducing drugs on hyperlipemia

A technology of Blautia and blood lipid-lowering drugs, applied in the field of medicine, can solve the problems of individual differences in berberine lipid-lowering, poor berberine responsiveness, and differences in berberine lipid-lowering efficacy, so as to reduce individual differences, Effect of enhancing responsiveness and enhancing lipid-lowering efficacy

Active Publication Date: 2020-01-17
BEIJING QUANTIHEALTH TECH CO LTD
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it has been found in practice that the lipid-lowering efficacy of berberine has great individual differences
Some patients take berberine to lower blood lipids very well, while other patients have poor response to berberine or even no response at all
The reasons for individual differences in lipid-lowering berberine are still unclear, which has become an important obstacle that seriously hinders the widespread application of berberine in clinical lipid-lowering, and has become an urgent problem to be solved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of blautia producta to preparation of products for strengthening treatment efficacy of blood lipid reducing drugs on hyperlipemia
  • Application of blautia producta to preparation of products for strengthening treatment efficacy of blood lipid reducing drugs on hyperlipemia
  • Application of blautia producta to preparation of products for strengthening treatment efficacy of blood lipid reducing drugs on hyperlipemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] This example is used to illustrate that berberine can significantly increase the abundance of the genus Blautia in the intestinal flora.

[0082] Twenty-four 8-week-old male ICR mice were randomly divided into 3 groups (normal group; model group (HFD group); berberine group (HFD+BBR group)), with 8 animals in each group. The normal group was given standard mouse feed, and the other groups were given high-fat feed D12492 supplied with 60% fat. The model group was given an equal volume of normal saline; the berberine group was given 200 mg / kg / day of berberine by intragastric administration. The animals were administered continuously for 30 days, and then 3 fresh feces were taken from each animal, and quickly frozen in liquid nitrogen for metagenomic sequencing analysis. The results are shown in Figure 1.

[0083] Principal component (PCA) analysis ( figure 1 (a)) and principal coordinates (PCoA) analysis ( figure 1 (b) b) shows that oral administration of berberine ...

Embodiment 2

[0085] This example is used to illustrate that the use of antibiotics to destroy the intestinal flora including the Blautia genus leads to the substantial disappearance of the hypolipidemic effect of berberine.

[0086] 40 8-week-old male ICR mice were randomly divided into 5 groups (normal group; model group (HFD group); berberine group (BBR group); antibiotic group; antibiotic + berberine group), 8 animals in each group . The normal group was given standard mouse feed, and the other groups were given high-fat feed D12492 supplied with 60% fat. Wherein the model group was given an equal volume of normal saline; the berberine group was given 200mg / kg / day of berberine by intragastric administration; the antibiotic group was given antibiotic combination (ampicillin+norfloxacin, each 300mg / kg / day); The +berberine group was given antibiotic combination (ampicillin + norfloxacin, each 300 mg / kg / day) and berberine (200 mg / kg / day). The animals were administered continuously for 30 ...

Embodiment 3

[0089] This example is used to illustrate that the culture supernatant of Blautia spp. of the present invention has the effect of inhibiting lipid accumulation in liver cells.

[0090] Cell culture: Human liver cancer HepG2 cells were purchased from the Cell Center of the Institute of Basic Medical Sciences, Peking Union Medical College Medical College. cells at 37°C, 5% CO 2 , cultured in high-glucose DMEM medium containing 10% by weight of fetal bovine serum (FBS) under saturated humidity conditions, and at the same time added double antibodies (100 μg / mL penicillin and 100 μg / mL streptomycin) in the medium at a ratio of 100:1 prime), and the culture medium was replaced with fresh medium every two days.

[0091] Working strain: Broutia is the Broutia of the present invention (the strain was preserved in the General Microbiology Center of China Committee for the Collection of Microorganisms on June 24, 2019 (Address: Beichen West Road, Chaoyang District, Beijing) No. 1 Cour...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines, in particular to an application of blautia producta to preparation of products for strengthening treatment efficacy of blood lipid reducing drugs on hyperlipemia, and provides an application of preparations for increasing bacterium level, uniformity or proportion of blautia producta (Blautia) to preparation of products for strengthening treatment efficacy of blood lipid reducing drugs on hyperlipemia, and a medical composition and an application of the medical composition to preparation of products for treating hyperlipaemia. The preparations for increasing the bacterium level, uniformity or proportion of blautia producta (Blautia) in intestinal flora of an examinee, the level, the uniformity or the proportion of beneficial microorganisms inthe examinee can be increased, and further the responsiveness of the examinee on a blood lipid reducing treatment method is strengthened, so that the lipid reducing efficacy of the blood lipid reducing drugs can be notably improved, and the individual difference is reduced.

Description

technical field [0001] The present invention relates to the field of medicine, in particular to preparations for improving the level, identity or ratio of bacteria of the genus Blautia in the intestinal flora of a subject and used in the preparation of enhanced blood lipid-lowering drugs for the treatment of hyperlipidemia The application of the efficacy product, a pharmaceutical composition and the application of the pharmaceutical composition in the preparation of products for treating hyperlipidemia. Background technique [0002] Hyperlipidemia refers to a disease in which the lipid content in the blood plasma is abnormally increased beyond the normal range due to abnormal metabolism or transport of lipids such as cholesterol and / or triglycerides in the body, which can cause a series of harmful effects on the human body. Healthy diseases, such as atherosclerosis, coronary heart disease and non-alcoholic fatty liver, etc. With the development of the economy and the change...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/74A61K45/06A61P3/06A61K31/22A61K31/366A61K31/40A61K31/405A61K31/4375A61K31/47A61K31/4709A61K31/505
CPCA61K31/22A61K31/366A61K31/40A61K31/405A61K31/4375A61K31/47A61K31/4709A61K31/505A61K35/74A61K45/06A61P3/06A61K2300/00
Inventor 李转羽赵柏闻吴城马艳艳杜建敏
Owner BEIJING QUANTIHEALTH TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com